BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months

AQST upcoming catalysts

Aquestive Therapeutics, Inc.: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 1 upcoming FDA decision event(s), and in the last 12 months 0 readout(s) and 1 FDA event(s). Subscribe to AQST (.ics).

Upcoming FDA decision events

DateEventStatusCompanyDrugSource
2027-03-16PDUFA date (company-disclosed)pendingAquestive Therapeutics, Inc. AQSTPDUFA March 16, 2027 - Aquestive Therapeutics, Inc.

Upcoming trial readouts

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No trials in this window.

FDA decision events, last 12 months

DateEventStatusCompanyDrugSource
2026-01-30Complete response lettercomplete responseAquestive Therapeutics Inc. AQSTdibutepinephrine sublingual filmCRL 2026-01-30: Aquestive Therapeutics Inc. NDA 219870 (dibutepinephrine sublingual film)

Trial readouts, last 12 months

ReadoutPhaseSponsorTrialConditionsStatusEnrollment
No readouts in the last 12 months.

Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA (openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score. Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP readout_calendar / fda_decisions. Not investment advice.